Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene

Padmaja Kunapuli, Kasyapa S. Chitta, John Kenneth Cowell

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.

Original languageEnglish (US)
Pages (from-to)3985-3991
Number of pages7
JournalOncogene
Volume22
Issue number26
DOIs
StatePublished - Jun 26 2003
Externally publishedYes

Fingerprint

Glioma
Cell Proliferation
Phenotype
Genes
Null Lymphocytes
Chromosomes, Human, Pair 10
Brain Neoplasms
Leucine
Agar
Membrane Proteins
Chromosomes
Gene Expression
Cell Line

Keywords

  • Brain tumors
  • LGI1
  • Leucine-rich repeat
  • Tumor invasion
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene. / Kunapuli, Padmaja; Chitta, Kasyapa S.; Cowell, John Kenneth.

In: Oncogene, Vol. 22, No. 26, 26.06.2003, p. 3985-3991.

Research output: Contribution to journalArticle

Kunapuli, Padmaja ; Chitta, Kasyapa S. ; Cowell, John Kenneth. / Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene. In: Oncogene. 2003 ; Vol. 22, No. 26. pp. 3985-3991.
@article{4ab93e1018d44292bb9458a6325a513e,
title = "Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene",
abstract = "The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.",
keywords = "Brain tumors, LGI1, Leucine-rich repeat, Tumor invasion, Tumor suppressor gene",
author = "Padmaja Kunapuli and Chitta, {Kasyapa S.} and Cowell, {John Kenneth}",
year = "2003",
month = "6",
day = "26",
doi = "10.1038/sj.onc.1206584",
language = "English (US)",
volume = "22",
pages = "3985--3991",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "26",

}

TY - JOUR

T1 - Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene

AU - Kunapuli, Padmaja

AU - Chitta, Kasyapa S.

AU - Cowell, John Kenneth

PY - 2003/6/26

Y1 - 2003/6/26

N2 - The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.

AB - The leucine-rich, glioma-inactivated (LGI1) gene, located in 10q24, was originally identified because it was interrupted and inactivated by a reciprocal chromosome translocation in the T98G glioma cell line. Loss of LGI1 expression in high-grade brain tumors is correlated with the frequent loss of chromosome 10 during progression of gliomas. To investigate whether this gene can suppress the malignant phenotype in glioma cells, we introduced the LGI1 gene into cells that do (U87) and do not (T98G and A172) express LGI1 endogenously. A172 and T98G cells showed a significant reduction in cell proliferation potential as a result of re-expression of LGI1, whereas U87 cells did not. Using BD matrigel matrix chamber assays we were also able to show that the migration ability of the reconstituted A172 and T98G cells was also reduced considerably. Finally, these reconstituted T98G and A172 cells showed a significant reduction in the ability to form colonies in soft agar compared with the parental cells. This analysis clearly demonstrates that re-expression of the LGI1 gene in glioma cells that were null for its activity can greatly reduce their malignant potential. These observations provide the opportunity to investigate the role of LGI1 in gliomagenesis and, since LGI1 is predicted to be a membrane-bound protein, potentially provides the opportunity to develop novel treatment strategies for malignant gliomas.

KW - Brain tumors

KW - LGI1

KW - Leucine-rich repeat

KW - Tumor invasion

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=0038678483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038678483&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206584

DO - 10.1038/sj.onc.1206584

M3 - Article

C2 - 12821932

AN - SCOPUS:0038678483

VL - 22

SP - 3985

EP - 3991

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 26

ER -